Clinical trials: Neoplasia Prostate
Prostate Cancer
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
The addition of abiraterone acetate to standard treatment of radiotherapy and short-term androgen deprivation will increase the frequency of undetectable PSA.
- Trial name
- NCT01717053
- Testing
- Abiraterone acetate, Androgen deprivation, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Prostate Cancer
Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer
The purpose of this phase 2, open-label, single-arm, multidose, multicenter study is to investigate the effects of Orteronel plus Prednisone on the QT/QTc interval in patients with Metastatic Castration-Resistant Prostrate Cancer
- Trial name
- NCT01549951
- Testing
- Orteronel+Prednisone
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur.
- Conditions
- Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT04032704
- Testing
- ladiratuzumab vedotin, pembrolizumab
- Where
- 66 sites in United States, Australia and 4 more
- Volunteers
- 205 people
- Sponsor
- Seagen Inc.
Prostate Cancer
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.
- Trial name
- Mainsail (NCT00988208)
- Testing
- Lenalidomide, Docetaxel, Prednisone
- Where
- 210 sites in United States, Australia and 19 more
- Volunteers
- 1,059 people
- Sponsor
- Celgene
Prostate Cancer
RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers
This is a Phase II non-blinded randomized study evaluating men with oligometastatic prostate cancer lesions randomized (1:1) to stereotactic ablative radiation therapy (SABR) versus SBAR + Radium-223.
- Trial name
- RAVENS (NCT04037358)
- Testing
- Radium-223, stereotactic ablative radiotherapy (SABR)
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Performance Evaluation of the AMS CONTINUUM™ Device
1. To assess the safety of using the CONTINUUM™ device by monitoring the side effects and complications associated with the Device following a radical prostatectomy. 2.
- Trial name
- NCT00894933
- Testing
- CONTINUUM™
- Where
- 6 sites in United States
- Volunteers
- 33 people
- Sponsor
- American Medical Systems
Prostatic Neoplasms, Prostatic Cancer
Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines
Background: Metastatic castration resistant prostate cancer (mCRPC) keeps growing even when the amount of testosterone in the body is reduced to very low levels. mCRPC is incurable.
- Trial name
- NCT03481816
- Testing
- ETBX-071; adenoviral PSA vaccine, ETBX-061; adenoviral MUC1 vaccine, ETBX-051; adenoviral brachyury vaccine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Precancerous Condition, Prostate Cancer
Fish Oil and Green Tea Extract in Preventing Prostate Cancer in Patients Who Are at Risk for Developing Prostate Cancer
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of fish oil and/or green tea may prevent prostate cancer.
- Trial name
- NCT00253643
- Testing
- green tea catechin extract, fish oil
- Where
- 3 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
- Trial name
- S1216 (NCT01809691)
- Testing
- TAK-700, Bicalutamide
- Where
- 560 sites in United States
- Volunteers
- 1,313 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate Cancer
Multiple trials have shown the efficacy of estrogen therapy in metastatic prostate cancer, and most recently trials have supported the use of transdermal estrogens (patch) in the patient population with a decreased risk of…
- Trial name
- NCT00176644
- Testing
- Transdermal Estradiol
- Where
- 6 sites in United States
- Volunteers
- 23 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Adenocarcinoma
Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation
This randomized clinical trial studies how well cholecalciferol supplement works in treating patients with localized prostate cancer undergoing observation.
- Trial name
- NCT00887432
- Testing
- Cholecalciferol, Laboratory Biomarker Analysis, Patient Observation
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Roswell Park Cancer Institute
Prostate Cancer
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy
This is a single-arm pharmacodynamic study with mandatory metastatic tumor biopsies in men with castration-resistant prostate cancer.
- Trial name
- NCT02115828
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostatic Neoplasms
Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT
This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive…
- Trial name
- NCT03007732
- Testing
- Pembrolizumab, SD-101, Leuprolide acetate
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- David Oh
Urinary Incontinence, Prostate Cancer
Perioperative Post-Prostatectomy Incontinence Home Telehealth Program
Many men develop urine leakage after prostate cancer surgery. Usually it is temporary, but pelvic floor muscle training and exercise (including urine control strategies) have been shown to reduce the time to regaining urine…
- Trial name
- ProsTel (NCT01960998)
- Testing
- Pelvic Floor Muscle Training, Perioperative Care and Wetness Management
- Where
- 3 sites in United States
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer
This phase II trial studies how well itraconazole works in treating patients with biochemically relapsed prostate cancer. Itraconazole may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7
- Trial name
- NCT01787331
- Testing
- Itraconazole, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Francisco
Adenocarcinoma of the Prostate, Stage II Prostate Cancer
Finasteride in Treating Patients With Stage II Prostate Cancer Who Are Undergoing Surgery
This randomized phase II trial studies how well finasteride works in treating patients with stage II prostate cancer who are undergoing surgery. Testosterone can cause the growth of prostate cancer cells.
- Trial name
- NCT00438464
- Testing
- Finasteride, Prostatectomy, Laboratory biomarker analysis
- Where
- 8 sites in United States
- Volunteers
- 204 people
- Sponsor
- National Cancer Institute (NCI)
Castration-Resistant Prostate Cancer
Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer
The primary purpose of this research is to describe patient characteristics predictive of an imaging study positive for distant metastases in patients with castration-resistant prostate cancer and no known distant metastases.
- Trial name
- PREDICT (NCT01981109)
- Where
- 58 sites in United States
- Volunteers
- 225 people
- Sponsor
- Dendreon
Prostate Adenocarcinoma, PSA Failure
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment
The purpose of this research study is to see if recurrent prostate cancer can be identified using a special procedure called a positron emission tomography (PET) scan.
- Conditions
- Prostate Adenocarcinoma, PSA Failure, Recurrent Prostate Carcinoma
- Trial name
- NCT02673151
- Testing
- Computed Tomography (CT) scan, 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Andrei Iagaru
Anemia, Breast Cancer
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
This is a multicenter, international, prospective, observational study of patients who are receiving systemic chemotherapy for solid tumour cancers (breast, colorectal, ovarian, prostate, lung, bladder, endometrial, renal…
- Conditions
- Anemia, Breast Cancer, Cancer, Colorectal Cancer
- Trial name
- NCT01444456
- Where
- 117 sites in Austria, Belgium and 7 more
- Volunteers
- 1,262 people
- Sponsor
- Amgen
Prostate Cancer
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
Phase I dose escalation study with combination of 177Lu-J591 and 177Lu-PSMA-617 using a dose-fractionated regimen will be performed in patients with documented progressive metastatic CRPC.
- Trial name
- NCT03545165
- Testing
- 177Lu-PSMA-617, 177Lu-J591, 68Ga-PSMA-HBED-CC
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.